New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease
Pharmaceutics · 16.02.2024 · 16 (2) · 281
DOI: 10.3390/pharmaceutics16020281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 16.02.2024. Verfasst von Leo Bon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Portuguese Fundação para a Ciência e Tecnologia (FCT), project GAinPD_SC01, the Erasmus+ program.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most common form of dementia with no cure so far, probably due to the complexity of this multifactorial disease with diverse processes associated with its origin and progress. Several neuropathological hallmarks have been identified that encourage the search for new multitarget drugs. Therefore, following a multitarget approach, nine rivastigmine–indole (RIV-IND) hybrids (5a1-3, 5b1-3, 5c1-3) were designed, synthesized and evaluated for their multiple biological properties and free radical scavenging activity, as potential multitarget anti-AD drugs. The molecular docking studies of these hybrids on the active center of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) suggest their capacity to act as dual enzyme inhibitors with probable greater disease-modifying impact relative to AChE-selective FDA-approved drugs. Compounds 5a3 (IC50 = 10.9 µM) and 5c3 (IC50 = 26.8 µM) revealed higher AChE inhibition than the parent RIV drug. Radical scavenging assays demonstrated that all the hybrids containing a hydroxyl substituent in the IND moiety (5a2-3, 5b2-3, 5c2-3) have good antioxidant activity (EC50 7.8–20.7 µM). The most effective inhibitors of Aβ42 self-aggregation are 5a3, 5b3 and 5c3 (47.8–55.5%), and compounds 5b2 and 5c2 can prevent the toxicity induced by Aβ1-42 to cells. The in silico evaluation of the drug-likeness of the hybrids also showed that all the compounds seem to have potential oral availability. Overall, within this class of RIV-IND hybrids, 5a3 and 5c3 appear as lead compounds for anti-AD drug candidates, deserving further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal.
- CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal.
- Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal.
ORCID-Profile: Leo Bon, Inês Dias, Inês Melo-Marques, Sandra M Cardoso, Sílvia Chaves, M Amélia Santos
Förderung
- the Portuguese Fundação para a Ciência e Tecnologia (FCT)
- project GAinPD_SC01
- the Erasmus+ program
Zitieren
APA
Bon, L., Banaś, A., Dias, I., Melo-Marques, I., Cardoso, S. M., Chaves, S., & Santos, M. A. (2024). New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease. Pharmaceutics, 16(2), 281. https://doi.org/10.3390/pharmaceutics16020281
Vancouver
Bon L, Banaś A, Dias I, Melo-Marques I, Cardoso SM, Chaves S, et al. New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease. Pharmaceutics. 2024;16(2):281. doi:10.3390/pharmaceutics16020281
BibTeX
@article{Bon2024,
author = {Bon, Leo and Banaś, Angelika and Dias, Inês and Melo-Marques, Inês and Cardoso, Sandra M and Chaves, Sílvia and Santos, M Amélia},
title = {New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {2},
pages = {281},
doi = {10.3390/pharmaceutics16020281}
}
EUVIMED